Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Antibody Development for Brevetoxin Detection

by Global Biodefense Staff
August 4, 2014
Brevetoxin Antibody Research

The National Oceanic and Atmospheric Administration (NOAA) has a requirement for unique mouse monoclonal antibodies capable of detecting brevetoxin.

Brevetoxins are a group of similar neurotoxic compounds which are tasteless and odorless. Although toxicity can result from inhalational, dermal, or oral exposure, the most common route of exposure is by oral ingestion of contaminated shellfish.  Illness from oral ingestion is characterized by abdominal pain, vomiting, and diarrhea, paresthesias, reversal of hot and cold temperature sensation, vertigo, and ataxia.

The vendor shall provide the NOAA Center for Costal Fisheries and Habitat Research with three separate purified monoclonal antibodies which bind brevetoxin-2, 3. The monoclonal antibodies will be used in their laboratory to detect low levels brevetoxin in environmental samples.

The three monoclonal antibodies to be provided to NOAA by the vendor should:

  • Bind both brevetoxin -2 and -3 with similar efficiency, i.e. the estimated efficiency with which each monoclonal antibody binds brevetoxin-2 should be within 85% to 100% that at which it binds brevetoxin-3 and vice versa.
  • Be demonstrated as capable of detecting brevetoxin 2 and brevetoxin 3 at a concentration of 0.3 parts per billion in seawater.
  • Determine lowest concentration at which each of the monoclonal antibodies provided to NOAA detects brevetoxin-1.

For each of the three monoclonal antibodies meeting the three criteria stated above, the vendor will supply at least 5 milligrams of purified monoclonal antibody. The vendor will also supply 0.5 milligrams of stable (>95% of the label remains attached after 3 months) horse radish peroxidase labeled brevetoxin-2 which can be used in combination with the three monoclonal antibodies to detect low concentrations of brevetoxin in environmental samples.

Further details are available under Solicitation Number: EE-133C-14-RQ-0872. The response deadline is Aug 19, 2014.

Related resources on brevetoxins:

  • Neurotoxic Shellfish Poisoning (MDPI)
  • Advances in Monitoring and Toxicity Assessment of Brevetoxins in Shellfish (PubMed)
  • Harmful Algal Blooms (CDC)
  • Analysis of Three Brevetoxin-Associated Bottlenose Dolphin Mortality (PLOS One)
  • Procedures for Detoxification of Brevetoxins PbTx-2 and PbTx-3 (USAMRIID)
  • ECL-Based Competitive Displacement Immunoassay for Type-2 Brevetoxins (PubMed)
Tags: Request for Quotes

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC